Reported results
- Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026, compared to $17.6 million for the third quarter of 2025.
- Net product revenue from marketed dermatology products was $18.9 million for the third quarter of 2026, compared to $17.0 million for the third quarter of 2025.
- Consolidated research and development expenses were $1.7 million for the third quarter of 2026, compared to $0.2 million for the third quarter of 2025.
- Consolidated selling, general and administrative costs were $17.8 million for the third quarter of 2026, compared to $17.4 million for the third quarter of 2025.
- Consolidated net loss attributable to common stockholders was $7.9 million, or $0.23 per share basic and diluted, for the third quarter of 2026, compared to net income attributable to common stockholders of $3.7 million, or $0.13 per share basic and $0.11 per share diluted, for the third quarter of 2025.
- Consolidated cash and cash equivalents totaled $152.2 million as of September 30, 2026, compared to $79.4 million as of December 31, 2025.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
